Stop bleeding money on bad exits

Every dollar you lose on a bad exit is money you’ll never get back.

The truth is, most traders don’t blow up because of entries… they get destroyed at the exit.

They give back profits.

They hold too long.

They sell too soon.

But there’s a fix.

👉 Learn the proven strategy that protects your gains

Don’t let the market keep stealing from you. Protect your profits starting now.

Mark Soberman
NetPicks

P.S. Coach Jay reveals some critical secrets about Iron Condor trades.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT ADVICE. NetPicks Services are offered for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation or be relied upon as personalized financial advice. We are not financial advisors and cannot give personalized advice.  There is a risk of loss in all trading, and you may lose some or all of your original investment. Results presented are not typical.  Please review the full risk disclaimer:  https://www.netpicks.com/risk-disclosure This email was sent to pahovis@aol.comby info@netpicks.com

16211 N Scottsdale Rd, Suite A6A #295, Scottsdale, AZ 85254

One Click Unsubscribe 

Hey Trader,

Every dollar you lose on a bad exit is money you’ll never get back.

The truth is, most traders don’t blow up because of entries… they get destroyed at the exit.

They give back profits.

They hold too long.

They sell too soon.

But there’s a fix.

👉 Learn the proven strategy that protects your gains

Don’t let the market keep stealing from you. Protect your profits starting now.

Mark Soberman
NetPicks

P.S. Coach Jay reveals some critical secrets about Iron Condor trades.

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT ADVICE. NetPicks Services are offered for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation or be relied upon as personalized financial advice. We are not financial advisors and cannot give personalized advice.  There is a risk of loss in all trading, and you may lose some or all of your original investment. Results presented are not typical.  Please review the full risk disclaimer:  https://www.netpicks.com/risk-disclosure This email was sent to pahovis@aol.comby info@netpicks.com

16211 N Scottsdale Rd, Suite A6A #295, Scottsdale, AZ 85254

One Click Unsubscribe 

Concealed Carry Map: Get The Knowledge You Need To…

Concealed Carry Map: Get The Knowledge You Need To Confidently Carry
— Read on www.usconcealedcarry.com/uscca-info/guide/affiliate-partner/concealed-carry-map/

S&P 8,000? Wall Street Banks Bet Big on Double-Digit…

EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!

Hello Peter Anthony Hovis,

S&P 8,000? Wall Street Banks Bet Big on Double-Digit Gains in 2026

After last week’s relatively quiet week of trading, Wall Street will have another shortened week, with markets being closed on Thursday in observance of New Year’s Day.

We will receive employment reports from ADP and minutes from the Federal Reserve’s FOMC meeting on Wednesday. Other than that, few catalysts could bring major volume to this week’s trading.

Regardless, the positive outlook for 2026 could push stocks even higher over the next weeks, said Adam Turnquist, chief technical strategist for LPL Financial.

• “Momentum heading into year-end suggests a favorable setup for a positive Santa Claus Rally — a historically bullish signal for January and the year ahead,” said Turnquist.

Adam Turnquist, chief technical strategist for LPL Financial (Photo: Fox Business)

Indeed, JPMorgan Chase and HSBC believe the S&P 500 will hit 7,500 by year-end in 2026 — an about 8% gain from the current level. Morgan Stanley and Deutsche Bank see another double-digit year with 2026 targets of 7,800 and 8,000, respectively. The most bullish target would be a more than 15% gain.

This shows how bullish Wall Street is right now.

They just don’t see many negative catalysts that could drag stocks down next year.

• “Despite AI bubble and valuation concerns, we see current elevated multiples correctly anticipating above-trend earnings growth, an AI capex boom, rising shareholder payouts, and easier fiscal policy,” said JPMorgan lead equity strategist Dubravko Lakos-Bujas.

JPMorgan lead equity strategist Dubravko Lakos-Bujas (Photo: CNBC)

It is also a worst-kept secret on Wall Street that the economy is K-shaped, where higher-income households have been driving the bulk of spending and wealth growth, while lower-income households have struggled.

Not only that, Big Tech companies have spent a boatload of money on AI infrastructure with questionable profitability, while their stocks are trading at lofty valuations, and more tech companies are taking on debt to fund these projects.

Plus, the Federal Reserve is expected to pause its rate-cutting cycle at its January meeting.

There are risks to both sides, and traders will likely tread carefully over the next few weeks.

Insulet: Tapping into a 14M Patient Market

Today’s Stock Pick: Insulet Corporation (PODD)

Insulet Corporation is a medical device company, and it is best known for its Omnipod insulin delivery system for patients with diabetes.

Unlike traditional insulin pumps that require tubing, the Omnipod is a small, wearable pod that delivers insulin continuously and can be controlled wirelessly.

And, of course, it can be tracked on mobile phones.

(Source: Insulet)

It was the first AID (Automated Insulin Delivery) system to be cleared by the FDA for both type 1 and type 2 diabetes in the USA.

At its core, an AID system is made up of three key parts: a continuous glucose monitor (CGM), an insulin pump (or pod), and a smart algorithm that ties them together.

The CGM continuously reads your glucose levels and sends that data to the controller (either the pump or an associated app). Every few minutes, typically around every five minutes, the algorithm calculates whether to increase, decrease, or pause insulin delivery so your levels stay in range. It’s essentially mimicking how a healthy pancreas would respond to your body’s changing needs.

The AID system is highly popular, and Insulet was the #1 most requested and prescribed AID system.

(Source: Insulet)

Insulet has raced ahead to maintain its leadership in the AID system. It is available in more than 47,000 U.S. pharmacies and is the only AID system that is covered by Medicare Part D.

(Source: Insulet)

The market is large and under-penetrated. The company estimates that there is about 14 million total addressable market of patients, and Insulet is only starting to penetrate the market.

(Source: Insulet)

The financials are world-class. Its revenue grew ~24% CAGR from 2020 to 2025. Gross margin expanded by 660 basis points to 71%. Adjusted operating margin skyrocketed from 7.3% in 2020 to about 17% this year.

So, this company has a strong product and a strong business model, making it a powerful combination.

(Source: Insulet)

Insulet expects another good year with 28% to 29% revenue growth for this year. Clearly, the momentum isn’t slowing down. (Remember that its CAGR was 24% in the last four years.) 

(Source: Insulet)

Bottom line: Insulet has developed a revolutionary product, and it has fantastic margins. With the market largely under-penetrated, the stock has a bright future.

 EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!

 

 

© All Rights Reserved, Trade Alliance

Unsubscribe | Manage Preferences

Wall Street Is Warming Up to Health Care Again

You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please unsubscribe here.

Prefer to view this content on our website? Click here.

---

Dear Fellow Investor,

Health Care’s Quiet Rotation Is Broadening: 3 Stocks Positioned to Benefit

Health care is quietly stepping back into the spotlight, and the most interesting part is that it is not behaving like a purely defensive trade.

Yes, health care has historically served as a steadier corner of the market during periods of uncertainty. But the recent shift has a different feel: the sector has flashed a rare historical signal, one that has not appeared often over the last few decades. When this type of setup has emerged in prior cycles, health care has often gone on to deliver meaningful relative outperformance.

The second notable detail is how the move has developed. For much of the year, gains were concentrated in a relatively small cluster of high-quality leaders, exactly the kind of narrow participation that can make a sector rally look stronger than it really is. Narrow leadership can persist, but it is also vulnerable: if the leaders stall, the entire theme can fade quickly.

That is why the current phase matters. What began as a “stealth rotation” is now broadening. More companies are joining the uptrend, and investor attention is expanding from a handful of familiar winners to a deeper bench across the industry. In market terms, improving breadth is often what turns a short-lived move into a more durable trend because it suggests the bid is not reliant on one or two names carrying the whole group.

For long-term investors, this kind of broadening can be a meaningful tell. When participation improves, it can indicate that the market is starting to price in better fundamentals across the sector: stabilizing demand, a more constructive earnings outlook, improving visibility, or even a shift in how investors value cash flows. And in health care specifically, broadening participation can also reflect a rotation toward businesses with recurring demand drivers that are less sensitive to the economic cycle.

With that backdrop, here is a look at three health care stocks that appear well positioned to benefit from a stronger, broader sector tape – supported by buy ratings from major firms and constructive implied upside to price targets.

---

Company: Agilent Technologies (SYM: A)
Picks-and-shovels exposure to life sciences and diagnostics
Recent Price: $141.74
Price Target: $168.08
Firms with Buy Rating: Morgan Stanley, Goldman Sachs, UBS

Agilent operates as an applications-focused provider to the life sciences, diagnostics, and applied chemical markets. Its business spans three segments, Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab, giving it broad exposure to the tools and services that support research, testing, and clinical workflows.

From an investor perspective, Agilent is often viewed as a “picks-and-shovels” way to participate in long-run health care and biotech innovation. Instead of betting on the success of a single drug, it sells essential instruments, consumables, and services that are used across many customers and end markets. In many cycles, that positioning can translate into a more resilient demand profile, especially when the company has a meaningful installed base and recurring service or consumables revenue.

Why might it benefit as the rotation broadens? When breadth improves in health care, it is often because investors are looking beyond headline drug makers and into the ecosystem that supports the entire innovation pipeline. As confidence improves around research activity, diagnostics demand, or clinical testing volumes, the market frequently re-rates the enabling platforms that sit behind the scenes.

Analyst support from multiple major firms suggests confidence in the company’s ability to execute through the next phase. The implied upside to target also indicates that, even after recent strength in parts of health care, some on the Street still see valuation room if fundamentals and sentiment continue to firm.

What to watch into 2026: order trends, lab spending cycles, and whether the mix continues to favor higher-value workflow solutions, factors that can influence both growth and margin structure.

---

Trading Whisperer

Wall Street’s New ETF Targets Global Money Movement

Money movement is changing faster than anyone expected.

Data centers run 24 hours. E-commerce runs 24 hours. Now finance is racing to catch up.

A newly listed ETF just opened the door to that evolution, offering a direct play on instant settlement through a simple, US listed wrapper.

Second-level finality. Institutional custody.

You trade it like any other fund. It reports like any other fund.

And while others chase hype, this product is built for discipline. Single asset exposure, no leverage, no hidden overlays, and a clear 0.50% sponsor fee.*

Every previous digital-asset ETF proved the appetite. Strong volume. Rapid AUM. A growing share of portfolios that used to avoid the space entirely.

This one brings that same structure to the payments side, the part of finance where efficiency actually pays.

The window to get in early is open. Learn more now.

Get the symbol before the crowd.

---

Company: AbbVie (SYM: ABBV)
A scale biopharma story with multiple franchises
Recent Price: $223.58
Price Target: $248.67
Firms with Buy Rating: HSBC, Piper Sandler, J.P. Morgan

AbbVie is a research-based biopharmaceutical company with a broad global portfolio spanning immunology, oncology, neuroscience, eye care, virology, and more. Investors most commonly associate AbbVie with major immunology therapies, historically Humira and, increasingly, newer therapies such as Skyrizi and Rinvoq, alongside a wide set of other branded medicines and aesthetics products.

In a broadening health care tape, AbbVie can stand out for a different reason than tools companies: it combines scale, cash flow, and diversified end markets. When investors re-engage with health care beyond the “defensive” framing, large, profitable biopharma companies with multiple growth drivers and strong commercial execution often re-enter the conversation as core holdings, not just tactical positions.

The appeal is typically a blend of durability and optionality:

• Durability because demand for many therapies is not tightly linked to GDP growth.
• Optionality because successful drug franchises, label expansions, and pipeline progress can create upside that is not always reflected in near-term numbers.

Analyst buy ratings across multiple firms suggest a constructive outlook on AbbVie’s ability to sustain performance as its portfolio evolves. The gap between the recent price and target is not extreme, but it still implies further upside if execution and earnings visibility remain strong.

What to watch into 2026: continued performance across key franchises, competitive dynamics in major therapeutic areas, and any pipeline catalysts that could expand the company’s growth profile.

---

Crypto 101

Get in before the new year rally hits

Let me tell you something about memecoins…when they move, they move FAST.

We’re not talking about slow, steady 20% gains over months. We’re talking about:

→ 600% in a single day
→ 1,100% in 48 hours
→ 8,200% in 5 months

That’s the kind of speed we’ve seen from my analysts Brian and Joe, who have developed a system for identifying memecoins before they explode.

The market is oversold. Fear is everywhere. Most investors are sitting on the sidelines waiting for “confirmation.”

But January has historically been one of crypto’s strongest months. A new year rally could be building as we speak. And when momentum returns to the market, memecoins don’t just participate…they lead.

Brian and Joe just flagged their #1 memecoin for January 2026. It’s still trading for pennies. It has viral energy, real utility, and a capped supply with a burn mechanism built in.

You can get the full report—what the coin is, how to buy it, and exactly what to expect—right now:
Get the #1 Memecoin for January 2026 here

---

Company: Thermo Fisher Scientific (SYM: TMO)
A category leader across the life science stack
Recent Price: $567.36
Price Target: $631.80
Firms with Buy Rating: Goldman Sachs, Morgan Stanley, Barclays

Thermo Fisher is one of the most strategically important companies in the life sciences ecosystem. It provides solutions across analytical instruments, specialty diagnostics, lab products, and biopharma services, selling everything from research consumables to sophisticated instrumentation and services supporting drug development and manufacturing.

Thermo Fisher’s breadth matters. In a sector rotation that is broadening, businesses with multiple demand drivers can be especially attractive because they are not dependent on one narrow pocket of the industry. The company’s segments span research and discovery, clinical and diagnostic testing, and bioproduction services, areas that can take turns leading depending on the cycle.

Analysts who like Thermo Fisher often point to a few structural strengths:

1. Scale and customer reach: It is embedded across pharma, biotech, academia, government, and industrial markets.
2. Recurring demand: Many product categories are consumables- or service-heavy, supporting repeat purchases.
3. Strategic positioning in biopharma services:Outsourcing trends and the complexity of biologics manufacturing can support long-run demand for specialized capabilities.

The implied upside to the target suggests analysts see room for appreciation if the market continues to reward health care “infrastructure” businesses as the rotation widens.

What to watch into 2026: biopharma funding and production trends, research activity levels, and how management balances growth and margin priorities across segments.

---

Paradigm Press

This Backdoor Play on Starlink’s IPO for Less than $100?Whenever Elon Musk goes “all in” on something, it always generates HUGE excitement and opportunity.
 
His latest project, Starlink – with its mission to provide satellite Internet to every corner of the globe – is no exception.
 
And one man says it will soon go public, at an estimated $100 BILLION valuation.
 
That would make it the biggest IPO in HISTORY…
 
Roughly 228X BIGGER than Amazon’s IPO.
 
Today, investing legend James Altucher has uncovered a smart, unconventional way to potentially benefit from the impending Starlink IPO…
 
This backdoor play lets savvy investors like you engage with Starlink’s promise without the need for direct initial IPO access.

Click here to learn how.

---

What other stocks do you have your eye on heading into 2026? What other sectors of the market are you currently interested in? Hit “reply” to this email and let us know your thoughts!

Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Canary XRP ETF (NASDAQ:XRPC). The compensation consists of up to $6,500 and was received/will be received from Market Jar Media.

This communication should not be considered as an endorsement of the securities of adviser Canary XRP ETF (NASDAQ:XRPC) and we are not responsible for any errors or omissions in any information provided about the securities of Canary XRP ETF (NASDAQ:XRPC) by Trading Whisperer or Market Jar Media.

We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.

This disclosure is made as of 12/29/25.

*Brokerage commissions apply and will reduce returns

For standardized returns of the Canary XRP ETF, please visit [XRP ETF – Canary Capital]. Past performance does not guarantee future results.

The Fund’s investment objectives, risks, charges and expenses should be considered before investing. 

The prospectus contains this and other important information, and it may be obtained at https://etfs.canary.capital/XRPC/prospectus/. Read it carefully before investing.
The Fund is not an investment company registered under the Investment Company Act of 1940 (the “1940 Act”), and therefore is not subject to the same regulatory requirements as mutual funds or traditional ETFs registered under the 1940 Act.

Investing Involves Significant Risk. The loss of principal is possible. Canary XRP ETF (the “Fund”) may not be suitable for all investors. This document does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial advisor/financial consultant before making any investment decisions.

The fund is new with a limited operating history.

Digital assets, such as XRP, are a relatively new asset class, and the market for digital assets is subject to rapid changes and uncertainty. Digital assets are largely unregulated and digital asset investments may be more susceptible to fraud and manipulation than more regulated investments.

XRP is subject to unique and substantial risks, including significant price volatility and lack of liquidity, and theft. The value of an investment in the Fund could decline significantly and without warning, including to zero. XRP is subject to rapid price swings, including as a result of actions and statements by influencers and the media, changes in the supply of and demand for digital assets, and other factors. There is no assurance that XRP will maintain its value over the long-term.  The Fund is not actively managed and will not take any actions to take advantage, or mitigate the impacts, of volatility in the price of XRP. An investment in the Fund is not a direct investment in XRP. Investors will not have any rights that XRP holders have and will not have the right to receive any redemption proceeds in XRP. Shares of the Fund are generally bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Only Authorized Participants may trade directly with the Fund and only large blocks of Shares called “creation units.” Your brokerage commissions will reduce returns.

Paralel Distributors LLC serves as the marketing agent.  Paralel is unaffiliated with Canary Capital and Native Ads.

Our mailing address is: 
Behind the Markets, LLC 
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved. 
You’re receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.

Behind the Markets

Unsubscribe

Sharper Image

Sharper Image
— Read on sharperimage.com/

Full Focus: See Why (NTRB) is Lighting Up Our…

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored by Nutriband Inc.

Krypton Street Just Announced (NTRB) Is Back At The Top Of Our Watchlist This Morning—Monday, December 29, 2025

Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly 

To Your Phone. Up To 10X Faster Than Email.

Take A Look At (NTRB) While It’s Still Early…

December 29 2025

Full Focus | See Why (NTRB) is Lighting Up Our Screens Right Now

Dear Reader,

Every so often, a name shows up that isn’t being hyped… it’s being built.

Quiet execution. Real alignment. And suddenly the backdrop starts changing in its favor—regulators, policy, timing, all moving in the same direction.

That’s the kind of setup Krypton Street looks for.

And this morning, Nutriband Inc. (NASDAQ: NTRB) is sitting at the top of our watchlist—Monday, December 29, 2025.

But keep in mind, (NTRB) has less than 5M shares listed in its float according to MarketWatch. When floats are this small, the potential exists for big moves if demand begins to shift.

Recently, Robert LeBoyer, Senior Vice President and Biotechnology Analyst at Noble Capital Markets, reiterated his $15 target on the company—which suggests over 230% upside potential from recent$4.50 levels.

And it’s not just because of the charts. On Dec. 18, (NTRB) issued a statementresponding to the U.S. Executive Order targeting illicit fen-tan-yl, drawing a clear line between illegal fen-tan-yl and FDA-regulated prescription therapies—while underscoring the urgent need for safer transdermal patches to reduce misuse and accidental exposure.

That same day, the company also signeda non-binding LOI with the Qvanta Group of Companies, an advanced technology organization developing quantum-ready AI infrastructure, to explore secure AI analytics and simulation tools that could support regulated pharmaceutical innovation tied to abuse-deterrent development.

And adding to the momentum, (NTRB)recently announced that Co-Founder Gareth Sheridan has returned as Chief Executive Officer, stepping back in to guide the company through the final stretch toward its 2026 NDA filing for AVERSA™ Fen-tan-yl.

Sheridan’s return restores founding leadership at a pivotal moment, as (NTRB) moves closer to what could become the world’s first FDA-approved abuse-deterrent opioid patch.

The company projects peak U.S. sales potential of $80M–$200M, with plans to expand access across major global healthcare markets.

Nutriband Inc. (NASDAQ: NTRB) is a transdermal pharmaceutical companydeveloping its proprietary AVERSA™ abuse-deterrent technology, designed to make commonly misused pain patches significantly harder to abuse while improving safety and patient comfort.

Rather than creating new chemical compounds, (NTRB) enhances existing FDA-approved dr-ugs by embedding its patented deterrent layers into proven transdermal delivery systems.

Under Sheridan’s renewed leadership, (NTRB) continues to operate with a structure built for both innovation and sustainability.

The company has three wholly owned subsidiaries—4P Therapeutics, Pocono Pharmaceuticals, and Active Intelligence—that collectively generate revenue and help offset research and development costs.

• 4P Therapeutics manages Nutriband’s clinical and regulatory programs.
• Pocono Pharmaceuticals provides contract manufacturing for clients ranging from small firms to global consumer brands like Reebok and KT Tape.
• Active Intelligence produces kinesiology and consumer health products, including a vitamin-based mosquito-repellent patchalready approved for sale in Central America.

This diversified foundation provides operational stability and financial discipline, allowing (NTRB) to advance its pharmaceutical pipeline without constantly relying on new capital raises—an approach management believes helps preserve long-term shareholder value and minimize dilution.

Lead Program: AVERSA Fen-tan-yl

(NTRB)’s lead focus, AVERSA Fen-tan-yl, aims to make powerful pain relief safer by preventing patch misuse and accidental exposure.

The patch includes a protective layer made from harmless but highly unpleasant ingredients—deterrents that make tampering nearly impossible.

To prepare for commercialization, (NTRB)partnered with Kindeva Dr-ug Delivery, a global leader in transdermal manufacturing, to complete large-scale production.

This milestone confirms the company’s ability to produce commercial-ready batches and move toward final testing.

The next major step is a human studycomparing AVERSA Fen-tan-yl with standard patches to measure resistance to tampering or extraction.

Following FDA meetings in September 2025, (NTRB) expects the study to begin in early 2026, with an FDA submission later in the year and potential approval by late 2026 or 2027.

Adding to this progress, (NTRB) signed an agreement on October 10, 2025, with Brand Institute, Inc., the world leader in dr-ug naming and identity development, to create the official brand name and visual identity for AVERSA™ Fen-tan-yl—another signal that commercial readiness is near.

Market Outlook and Sales Potential

A study commissioned by Advanced Health estimated that AVERSA Fen-tan-yl could bring in around $200M in annual sales after launch.

If regulators decide that all pain patches must include similar safety technology—something that’s possible once AVERSA proves its value—sales could grow toward $800M a year.

The same analysis also suggested that insurers may pay about 20% more for a safer, branded patch because it lowers the risk of patient harm and accidental exposure.

This potential comes at a time when many doctors have scaled back on prescribing Fen-tan-yl patches due to misuse concerns, leaving some chronic-pain patients with fewer options.

(NTRB)’s solution could help restore confidence among physicians and insurers by offering a patch that provides the same relief but with far fewer safety risks.

Intellectual Property and Platform Expansion

(NTRB) has built a strong foundation of patents that protect its technology in more than 45 countries, and new filings are expected to extend that protection until 2045.

The company doesn’t view AVERSA as just one product—it’s a platform that can be applied to other medications that face similar risks of misuse.

Next in line are two related patches:

• AVERSA Buprenorphine, aimed at treating opioid dependence and chronic pain.
• AVERSA Methylphenidate, designed for attention-deficit disorders.

Because the AVERSA system has already been proven, these follow-on products should move through development much faster—possibly within 6–12 months of the Fen-tan-yl patch approval.

Looking further ahead, (NTRB)’s team is also researching a needle-free insulin patch for people with type 2 diabetes.

While still early in development, it shows how the same transdermal technology could eventually reach beyond pain management.

Near-Term Milestones

Over the next 12 to 18 months, (NTRB)’sprogress will center around a few key steps:

• Receiving formal FDA feedbackfrom the September 2025 meeting.
• Launching the human abuse studyin early 2026 and reviewing results within about three months.
• Preparing the FDA filing later in 2026 with manufacturing data from Kindeva.
• Beginning work on the next AVERSA-based patches for buprenorphine and methylphenidate.

Together, these milestones make 2026 a potentially defining year for (NTRB)—one that could move the company from research mode to full commercial readiness.

7 Factors Putting (NTRB) At The Top Of Our Watchlist This Morning

—Monday, December 29, 2025

1. Potential Catalysts Ahead: With a human study expected in early 2026 and a planned filing later in the year, (NTRB)has a clearly defined timeline that could keep news flow active.

2. Analyst Target: With Noble Capital Markets reiterating a $15 target, (NTRB)has a widely watched reference point that suggests over 230% upside potentialfrom recent $4.50 levels and keeps it front-and-center for many active market participants.

3. Limited Float: With less than 5M shares listed as being available to the public, (NTRB)’s small float has the potential to witness big moves if demand begins to shift.

4. Federal Spotlight: After responding to a U.S. Executive Order focused on illicit fen-tan-yl, (NTRB) highlighted the growing need for safer prescription patch solutions that reduce misuse risk.

5. AI Optionality: By signing a non-binding LOI with Qvanta to explore secure AI analytics and simulation tools, (NTRB)introduced a forward-looking layer of innovation tied to regulated pharmaceutical development.

6. Founder Return: With Co-Founder Gareth Sheridan back as CEO, (NTRB)has restored founding leadership as it moves toward major 2026 regulatory milestones.

7. Commercial Readiness: After completing scale-up work with Kindeva and signing Brand Institute for naming and identity development, (NTRB) is showing multiple signs of preparation for the next stage.

Take A Look At (NTRB) While It’s Still Early…

When you step back and connect the dots, it becomes clear why attention around (NTRB) is building.

With less than 5M shares listed as being available to the public, even small shifts in demand can create sharp reactions — and that dynamic becomes even more notable when the company is backed by a widely watched analyst view.

Noble Capital Markets recently reiterated a $15 target, which suggests over 230% upside potential from recent $4.50 levels, putting (NTRB) firmly on the screen for active market participants.

Add in the federal spotlight on safer prescription patch solutions, a forward-looking LOI exploring secure AI and simulation tools, and the return of Co-Founder Gareth Sheridan to guide the company through its 2026 roadmap, and this story starts to look more structured than speculative.

With manufacturing scale-up progress completed, naming work underway, and a clear clinical and regulatory timeline ahead, (NTRB) has multiple catalysts that could keep news flow active.

(NTRB) is front and center for us right now.

Make sure you get (NTRB) on your screen while it’s still early.

I’ll be back shortly—my next update could hit any moment.

Sincerely,

Alex Ramsay

Co-Founder / Managing Editor

Krypton Street Newsletter

KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 10/28/2025 and ending on 12/29/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Media 1717 LLC has been paid nine thousand USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid sixty four thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US).

Neither Media 1717 LLC, TD Media LLC and their member own shares of (NTRB:US).

Please see important disclosure information here: https://kryptonstreet.com/disclosure/ntrb-lUeCL/#detailsMedia 1717 LLC6586 W Atlantic AveUnit #2086Delray Beach, FL 33446UnsubscribeUpdate Profile | Constant Contact Data NoticeSent by alex@kryptonstreet.com

IQST – New NASDAQ Alert

*Read Disclaimer Sponsored Content

December 29, 2025 | Unsubscribe 

Hello!

New Alert: IQSTEL Inc. (NASDAQ: IQST)

IQST is our brand new NASDAQ high growth alert. 

This is a hidden gem opportunity that not many have seen. 

They just listed on the NASDAQ earlier this year. 

Plus, the company is in one of the hottest sectors today – AI. 

The chart setup alone is pointing to a massive breakout opportunity. 

This means that momentum can build very quickly. 

Currently, IQST is trading well below key technical levels: 

• 20-day moving average: 3.65 – +22% above Friday’s close
• 50-day moving average: 4.53 – +51% above Friday’s close

Plus, IQST has a RSI of just 24. 

That indicates there is big upside potential. 

In addition, the company has announced multiple accomplishments recently that could have been overlooked by markets (including news this morning). 

IQST is a NASDAQ listed “Global Connectivity, AI, and Digital Corporation” 

IQST provides “advanced solutions across Telecom, High-Tech Telecom Services, Fintech, AI-Powered Telecom Platforms, and Cybersecurity”. 

IQST has “operations in 21 countries and a team of 100 employees”, and “serves a broad global customer base with high-value, high-margin services” 

IQST sells “hundreds of millions of dollars in services to over 600 of the largest telecom operators around the world”. 

As the company notes in their most recent December 15 press release: 

• “Backed by a strong and scalable business platform, the company is forecasting $340 million in revenue for FY-2025, reinforcing its trajectory toward becoming a $1 billion tech-driven enterprise by 2027.”

Here are some of the company’s Q3 2025 Strategic Highlights from their November 14 press release: 

• “Acquisition of Globetopper (51% Ownership)”:
  • “Strengthens IQSTEL’s global footprint and establishes a revenue mix of approximately 80% Telecom and 20% Fintech, enhancing diversification and profitability.”
• “Debt-Free Status”:
  • “IQSTEL confirms it is a dilutive debt-free company, with no convertible notes and no warrants outstanding, providing shareholders with a clean, efficient capital structure.”
• “AI-Powered Call Center Services Launched”:
  • “IQSTEL successfully launched its AI-driven Call Center Services – www.contactcenter.iqstel.com – powered by its proprietary AI engine IQ2Call.ai, developed internally by the company’s AI division.”

IQST has announced multiple accomplishments recently. 

At the end of October, the company announced: 

• “IQST – IQSTEL Announces $430 Million Organic Revenue Forecast for 2026, Reflecting 26% Organic Growth and Building on Strong Momentum”

In November, the company announced: 

“IQST – IQSTEL Reports Record Q3 2025 Results: $102.8 Million Quarterly Revenue, 42% Sequential Growth, and Strengthened Balance Sheet”

“Q3 2025 Financial Highlights” (from this press release): 

• “Revenue (Q3 2025): $102.8 million vs. $72.1 million in Q2 2025 (+42% QoQ) and compared to $54.2 million in Q3 2024 (+90% YoY)”
• “Revenue (9 months ended Sept 30): $232.6 million vs. $184.3 million in 2024 (+26% YoY)”
• “Gross Revenue: $118.5 million (including $15.7 million intercompany revenue, highlighting strong subsidiary synergy)”
• “Adjusted EBITDA (Q3 2025): $683,189 (Telecom: $604,514 | Fintech: $78,675)”
• “Revenue Run Rate: $411.5 million”
• “Adjusted EBITDA Run Rate: $2.73 million”
• “Assets: $46.8 million ($12.23 per share) as of September 30, 2025”
• “Stockholders’ Equity: $17.8 million ($4.66 per share) as of September 30, 2025 which represent an increase of 50.02% with respect to $11.9 million as of December 31, 2024”
• “Shares Outstanding: 3,832,470 as of September 30, 2025”

CEO Commentary (from this press release): 

“Our third quarter results highlight not only our consistent growth but the strength of the company’s fundamentals,” said Leandro Iglesias, CEO of IQSTEL.

“With $12.23 in assets per share and $4.66 in equity per share, IQSTEL is financially stronger than ever. We remain deeply committed to increasing shareholder value through profitable growth, innovation, and disciplined execution.”

As the company further explains: 

“Our business model is proven. Our operating businesses have generated positive adjusted EBITDA and positive net income for several quarters in a row, demonstrating sustained operational profitability. While our rapid expansion required financing that temporarily affected consolidated results, these costs have been amortized in a short period. Having reached critical mass, IQSTEL’s bottom line is now beginning to accelerate — and investors should expect this profitability trend to strengthen in the coming quarters.”

Iglesias added: 

“After becoming a dilutive debt-free company and achieving record revenue growth, IQSTEL is now in the best business and corporate shape in its history to reach our $15 million EBITDA target in 2026. We are building the foundation for a billion-dollar global corporation — one quarter at a time.”

Looking ahead, as the company explains: 

“IQSTEL remains fully on track to achieve its 2025 revenue forecast of $340 million and has already announced an organic revenue forecast of $430 million for 2026, representing 26% year-over-year organic growth.”

“With a revenue run rate above $400 million, zero dilutive debt, and a solid equity position, IQSTEL continues its transformation into one of the fastest-growing technology corporations listed on Nasdaq — combining Connectivity, AI, Fintech, and Cybersecurity into one powerful global platform.”

“Thanks to its strong balance sheet, explosive revenue growth, and its strategic position in both the telecommunications and technology markets, IQSTEL could become an attractive acquisition target for larger industry players seeking expansion in high-growth digital and AI-driven sectors.”

Most recently, in December, the company announced: 

“IQST – IQSTEL Confirms $500,000 Shareholder Dividend to Be Paid on December 30th in Free-Trading IQST Common Shares as Part of Its Long-Term Shareholder Value Strategy”

IQSTEL CEO Leandro Iglesias stated (in this press release): 

“We are proud of who we are as a company and what we have achieved together. IQSTEL has fulfilled every promise we made to our shareholders—not only delivering strong operating results, but also tangible, measurable shareholder value. Now, as we enter a new stage with a clear path toward becoming a $1 billion revenue corporation, our commitment to our shareholders is stronger than ever. Beginning this year, IQSTEL intends to issue dividends annually, tied directly to our performance and growth. This $500,000 dividend is a testament to our vision, our execution, and our unwavering dedication to rewarding those who believe in our mission.”

The company also announced: 

“IQSTEL Announces 2025 Accomplishments and Strategic Priorities for 2026 in New Interview”

• “2025 Achievements Lay Foundation for Accelerated 2026 Expansion”

Here are some of the comments from this press release: 

While discussing the strengthened financial position of IQSTEL in 2025, CFO Alvaro Cardona stated that, “Having a company that is debt‑free, with no convertible notes and no outstanding warrants, gives us a uniquely strong financial foundation. Our balance sheet remains solid, and shareholder equity continues to grow year after year, reflecting the disciplined approach we’ve taken to managing capital. This strength provides us with significant operating flexibility and the ability to pursue accretive acquisitions with confidence. It allows us to evaluate opportunities not from a position of necessity, but from a position of strength, ensuring that every move we make is aligned with long‑term value creation for our shareholders, clients, and partners.”

In addition, the company also announced: 

“IQST – IQSTEL Announces First Dividend Distribution – Record Date Set for Today, December 15, 2025”

CEO Commentary (from this press release): 

“This year has been truly amazing for IQSTEL,” said Leandro Iglesias, President and CEO of IQSTEL. “We successfully uplisted to Nasdaq, achieved a $400 million revenue run rate ahead of plan, and reached a $2.7 million EBITDA run rate. Our Fintech business now represents approximately 20% of our revenue stream, we have added Cybersecurity to our high-tech, high-margin value proposition, and today we are proud to deliver the first dividend in company history to our loyal shareholders.

“This dividend marks an excellent starting point as we continue executing our strategy toward a $15 million EBITDA run rate next year and our long-term goal of achieving a $1 billion revenue run rate by 2027.”

This morning, the company announced: 

• “IQST – IQSTEL Recaps a Transformational 2025, Highlighting NASDAQ Uplisting, Record Revenue Run Rate, Strategic Expansion, and First-Ever Dividend”

IQST could be positioned for a big breakout higher. 

Make sure to do your own due diligence. 

Sources: Presentation, PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, Website, Chart

Happy Trading!

SmallCapStocks Team

Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.

DISCLAIMER:

You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”).  The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov; the Financial Industry Regulatory Authority (the “FINRA”) at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

Owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 12/23/25 for the distribution of this advertisement about IQST dated 12/29/25. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.

You are receiving this report/release because you subscribed to receive it at our website or through a third-party site.  All our newsletters include an “unsubscribe” link, and you can remove yourself at any time from our newsletters by clicking on that “unsubscribe” link. You can also contact us at info@SmallCapStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:

www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.

Update your email preferences or unsubscribe here

© 2025 Small Cap Stocks 

1969 South Alafaya Trail
Orlando, Florida 32828, United States of AmericaPowered by beehiivTerms of Service 

Don’s Trading Desk

Financial Newsletter
— Read on tradingdesk.beehiiv.com/

Trump Planning to Use Public Law 63-43: Prepare Now

AN OXFORD CLUB PUBLICATION

Loyal reader since August 2025 

Editor’s Note: We’re sharing a brief but important alert from Jim Rickards. He’s uncovered a little-known federal law that he believes could trigger a major market shift in 2026—and he explains why in a short presentation. If you have any money in the markets, this is worth your attention.

You can watch his briefing now or continue below for Jim’s full message.

– James Ogletree, Senior Managing Editor

---

Trump Planning to Use Public Law 63-43: Prepare Now 

Dear reader,

If you have any money in the markets…

Public Law 63-43 (see it below) could have a huge impact on your wealth in 2026.

You see, three simple words buried deep in Section 10 of this 112-year old little-known law…

Grants President Trump the power to make this critical move on May 15th.

President Trump himself has confirmed the plan is already in motion.

As a former advisor to the CIA, the Pentagon and the White House…

I know for a fact there are meetings taking place right now behind closed doors in the White House.

His entire administration is preparing for it.

I recommend you prepare as well.

Click here to see the details because I believe this single move will help unleash a historical supercycle of wealth…

That “gift” will make a lot of patriots rich on America’s 250th anniversary.

Regards,

Jim Rickards 
Former advisor to the CIA, the Pentagon and the White House

You are receiving this email because you subscribed to Wealthy Retirement.
Wealthy Retirement is published by The Oxford Club.

To stop receiving special invitations and offers from Wealthy Retirement, please click here.
Please note: This will not impact the fulfillment of your subscription in any way.

Questions? Check out our FAQs. Trying to reach us? Contact us here.
Please do not reply to this email as it goes to an unmonitored inbox.

Privacy Policy | Whitelist Wealthy Retirement

© 2025 The Oxford Club, LLC All Rights Reserved
The Oxford Club | 105 West Monument Street | Baltimore, MD 21201
North America: 866.237.0436 | International: 443.353.4540
Oxfordclub.com

Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.

Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.

REF: 000142349377

Double Your Gift | North Shore Animal League America…

Double Your Gift | North Shore Animal League America – North Shore Animal League America
— Read on takeaction.animalleague.org/site/